Engeneic Ltd., of New York, said preclinical findings published in Molecular Cancer Therapeutics highlight the potential of the company's targeted, bacterially derived nanocells to enhance the delivery of intensive chemotherapy to tumors while limiting toxicity to normal tissues in aggressive pediatric malignancies, including neuroblastoma.